Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03552211
Other study ID # CHU-388
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date May 30, 2018
Est. completion date April 30, 2019

Study information

Verified date May 2018
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: High dose biotin is a therapeutic option for French progressive Multiple Sclerosis (MS) patients, without relapse for at least one year, since June 1, 2016. Despite the inflammatory activity of progressive forms of MS is known to be low, several publications mentioned clinical and/or radiological activity for biotin-treated patients.

Objectives:

1. To determine if high dose biotin increase the clinical inflammatory activity of patients with a progressive form of MS.

2. To compare the clinical characteristics of the relapses that occurred with biotin or not.

3. To describe the characteristics of the patients with a clinical inflammatory activity with biotin.

Methods: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat. The main judgment criterion is the annualized relapse rate (ARR) from the beginning of the biotin to the last evaluation available before the data extraction. A Student's t test will be used. A negative binomial modelling with relapses counting over a period of exposure and taking into account the inter and intra center variability will be used. The statistical tests will be adapted to the nature of the variables concerning the secondary judgment criteria.

Expected results: This French national study will provide a better knowledge of the inflammatory activity of the progressive forms of MS treated with high dose biotin. If an increased clinical inflammatory activity is highlighted with biotin a prospective study will be necessary to confirm the result before a specific information of the scientific community and the patients about this risk or even an amendment of prescription rules in order to secure the use of the product. On the contrary, the absence of increased risk of clinical inflammatory activity with biotin would help to reassure the prescriber and the patient about the innocuity of the treatment.


Description:

Investigators are going to recruit retrospectively all the patients treated with biotin since the product is available in France, in all French MS centers that agree to participate (maximum 30). They are going to collect through medical records, demographic data (as age, gender, MS center localization), but also data about the disease (as MS duration, primary progressive or secondary progressive MS), data about disability (with several Expanded Disability Status Scale -EDSS- scores at different time points) and data about treatments (as duration of biotin, existence of other concomitant disease-modifying therapy). For comparison, a control group without biotin is going also to be recruited from the European Database for Multiple Sclerosis (EDMUS). The same data as described above are going to be collected for the controls.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 3000
Est. completion date April 30, 2019
Est. primary completion date February 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- For the patients treated with biotin :

- progressive form of MS (primary or secondary)

- age between 18 and 80 years

- Expanded Disability Status Scale (EDSS) between 3 and 7.5 at the beginning of biotin

- treatment with biotin 300 mg per day at least one time, ongoing or stopped

- no relapse in the year preceding biotin introduction

- follow-up in an MS expert center

- For the controls :

- progressive form of MS (primary or secondary)

- age between 18 and 80 years

- Expanded Disability Status Scale (EDSS) between 3 and 7.5 at the baseline

- EDMUS data base fulfilled at least three times during the two previous years

- no relapse in the year preceding the baseline

- follow-up in an MS expert center

Exclusion Criteria:

- For all participants :

- other disease modifying therapy (DMT) than interferon, methotrexate, mycophenolate mofetil, azathioprine, rituximab, ocrelizumab

- For the controls :

- treatment with biotin actually or in the past

- follow-up in an MS expert center who do not provide exhaustive information about biotin

Study Design


Intervention

Drug:
biotin
This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Other:
propensity score
This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.

Locations

Country Name City State
France CHU Clermont-FERRAND Clermont-Ferrand

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand MedDay Pharmaceuticals SA, OFSEP (Observatoire Français de la Sclérose en Plaques), SFSEP (Société Francophone de la Sclérose en Plaques)

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relapses with biotin To determine if high dose biotin increases the clinical inflammatory activity of patients with a progressive form of MS using the annualized relapse rate (ARR) comparing to a control group at day 1 (through study completion, an average of 1 year)
Secondary Clinical characteristics of the relapses with biotin To compare the clinical characteristics of the relapses that occurred with biotin or not. at day 1 (through study completion, an average of 1 year)
Secondary Characteristics of patients with relapse with biotin To describe the characteristics of the patients with a clinical inflammatory activity with biotin at day 1 (through study completion, an average of 1 year)
See also
  Status Clinical Trial Phase
Completed NCT02282826 - A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis Phase 1
Completed NCT02804594 - A Study of Oxidative Pathways in MS Fatigue Phase 2
Completed NCT04120675 - Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis N/A
Completed NCT01719159 - Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis Phase 2
Recruiting NCT05740722 - Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis Phase 2
Completed NCT03980145 - G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis N/A
Completed NCT03269071 - Neural Stem Cell Transplantation in Multiple Sclerosis Patients Phase 1
Not yet recruiting NCT05811013 - Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis N/A
Not yet recruiting NCT04289909 - Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) N/A
Recruiting NCT05685784 - Multiple Sclerosis Prediction and Monitoring of Progression Study N/A
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Completed NCT03302806 - Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Recruiting NCT05441488 - Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04695080 - ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Phase 2/Phase 3
Recruiting NCT06451159 - A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis Phase 1
Completed NCT03423121 - A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis Phase 1/Phase 2
Terminated NCT02580669 - Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis N/A
Enrolling by invitation NCT05706220 - Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
Recruiting NCT01815632 - Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) Phase 2
Recruiting NCT01364246 - Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Phase 1/Phase 2